Peritoneal cancer treatment. (April 2014)

• Record Type: Journal Article
• Authors: Yonemura, Yutaka; Canbay, Emel; Endou, Yoshio; Ishibashi, Haruaki; Mizumoto, Akiyoshi; Miura, Masahiro; Li, Yan; Liu, Yan; Takeshita, Kazuyoshi; Ichinose, Masumi; Takao, Nobuyuki; Hirano, Masamitsu; Sako, Shouzou; Tsukiyama, Gorou
• Is Part Of: Expert opinion on pharmacotherapy. Volume 15:Number 5(2014)
• Page Start: 623
• Page End: 636
• Publication Date: 2014-04
• Subjects: Chemotherapy -- Periodicals; 615.5805
• DOI: 10.1517/14656566.2014.879571
• Languages: English
• ISSNs: 1465-6566

Abstract

<abstract> <title> <x xml:space="preserve">Abstract</x> </title> <p> <bold> <italic>Introduction:</italic> </bold> In the past, peritoneal surface malignancy (PSM) was considered as a final stage of cancer, and patients were offered the best supportive care. Recently, a new therapeutic alternative approach based on the combination of surgery with chemotherapy was developed. In this curative intent, the macroscopic disease was treated with cytoreductive surgery (CRS) combined with perioperative chemotherapy, including neoadjuvant chemotherapy, hyperthermic intraoperative intraperitoneal chemotherapy, extensive intraoperative peritoneal lavage and early postoperative intraperitoneal chemotherapy</p> <p> <bold> <italic>Areas covered:</italic> </bold> This article reviews the mechanisms of the formation of PSM, quantitative estimation of PSM and residual disease, multimodal treatment, value of laparoscopy, prognostic factors and patients' selection for the multimodal therapy.</p> <p> <bold> <italic>Expert opinion:</italic> </bold> Recent studies show that CRS plus intraperitoneal chemotherapy applications confer prolonged survival in patients with PSM from colorectal, gastric, ovarian, appendiceal mucinous carcinoma and diffuse malignant peritoneal mesothelioma. The comprehensive treatment is now justified as state-of-the-art for patients with peritoneal metastasis.</p> </abstract>